SGS Completes Expansion of Bioanalytical Testing Laboratory in France

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, October 2021
Volume 16
Issue 10

The expansion to SGS’s Poitiers facility in France is expected to improve the company’s drug development capabilities.

SGS announced the completion of expansions to its bioanalytical laboratory in Poitiers, France on Sept. 30, 2021. The addition consists of a new 800 m² building that houses additional drug development equipment and extra office space.

Included in the expansion are chromatography and immunoassay laboratories that are intended to dramatically increase production capacity. Additional capacities such as mass spectrometry, immunoanalysis, and cell-based bioassays will be added to the site’s existing capabilities.

The facility also adds new digital tools, such as customer relationship management and configure, price, quote software for contracting and monitoring. A large sample storage combined with bar code systems allows for storage of up to 800,000 samples at a time.

“The expansion comes at an exciting time,” said Walid Elbast, SGS’s general manager in France, in a company press release. “It allows us to meet increased demand in the area and shorten processes for our pharmaceutical clients. For me, this is a testimony to the outstanding teamwork of everyone involved and SGS’s continued investment in supporting innovation in the life sciences sector.”

Source: SGS

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content